ClinicalTrials.gg
CompletedNCT04330040SOLIUpdated Mar 10, 2025Results posted

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

A Phase 4 interventional study of Olaparib in Ovarian Cancer and Breast Cancer, sponsored by AstraZeneca. Completed at 16 sites in India. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
18th of 69
202 · median 97
Started
2020
with 5 others
Phase 4
3 of 69
1 open now
Registered
44th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 18th largest by enrollment, is one of 6 that started in 2020, is one of 3 in phase 4, and was the 44th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA (BReast CAncer gene) 1/2 Mutation

Read the detailed description

A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic Breast Cancer with germline BRCA(BReast CAncer gene)1/2 Mutation As per recommendation from DCGI(Drug Controller general of of India), the current phase-IV study is planned with the aim to assess the safety in Indian subjects receiving olaparib as per the approved label indications in India in accordance with the requirements of the Health Authorities of India. This study attempts to descriptively elucidate the safety of Olaparib in Indian subjects receiving olaparib as per the Indian regulatory approved indications in India. The data obtained from the present study will help to understand the safety profile of olaparib in Indian patients.

03

Conditions studied

  • Ovarian Cancer
  • Breast Cancer

Keywords

  • Ovarian Cancer; Breast Cancer, Olaparib
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written form prior to any mandatory study specific procedures..
  2. Female Subjects with ≥ 18 years of age
  3. Subjects receiving olaparib for the following indications in ovarian cancer:

    for the maintenance treatment of adult subjects with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy

  4. Subjects receiving olaparib for the following indication in breast cancer:

in subjects with deleterious or suspected deleterious gBRCAm, -negative breast cancer who have previously been treated with chemotherapy in the , adjuvant or metastatic setting. Subjects with HR-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment

Exclusion criteria

Exclusion Criteria:

  1. Patients with either the history of to of the study drug or to drugs with a similar chemical structure or class to the study drug.
  2. pregnant and/or lactating women.
  3. Patients with a previously or currently diagnosed MDS/ AML or pneumonitis.
  4. Patients who have not recovered sufficiently from prior surgery or anticancer treatment.
  5. Patients who have known history of or
  6. Patients with active infection such as TB.
  7. Participation in another clinical study with a study drug administered in the last 3 months
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Single Arm

    Intervention: Drug: Olaparib

    Drug: Olaparib

Interventions

06

What researchers measure

Primary outcomes

  1. Haematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and Platelets Parameters

    The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Comparison between the cohorts was not the objective for the study. The hematology data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment

    Time frame: Baseline to EOT (approximately 6 months)

  2. Haematology: Haemoglobin Parameters

    The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. The haemoglobin parameter data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment

    Time frame: Baseline to EOT (approximately 6 months)

  3. Number of Participants Who Experienced a Shift in Hematology Parameters to Results Classified as Below Normal at EOT

    The number of participants who experienced hematology results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment

    Time frame: Baseline to EOT (approximately 6 months)

  4. Number of Participants Who Experienced a Shift in Hemoglobin Parameters to Results Classified as Below Normal at EOT

    The number of participants who experienced hemoglobin results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented.. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment

    Time frame: Baseline to EOT (approximately 6 months)

  5. Number of Participants With Remarkable Changes in Clinical Chemistry Values Over Time as Assessed by Investigator

    The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment

    Time frame: Baseline to EOT (approximately 6 months)

  6. Number of Participants With Remarkable Changes in Physical Examination Over Time as Assessed by Investigator

    Abnormal clinically significant results at Baseline and EOT are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.

    Time frame: Baseline to EOT (approximately 6 months)

  7. Number of Participants With Remarkable Changes in Vital Signs Over Time as Assessed by Investigator

    The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment

    Time frame: Baseline to EOT (approximately 6 months)

  8. WHO Performance Status

    The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.

    Time frame: Baseline and End of study visit (200 days)

07

Results

Posted Mar 10, 2025

Participant flow

Participants who were prescribed olaparib by an independent clinical judgement of investigator in his/her routine practice based on locally approved prescribing information were eligible for screening under this study.

Participant flow — Overall Study
MilestoneOvarian CancerBreast CancerBoth Ovarian Cancer and Breast Cancer
Started163381
Completed104181
Not completed59200
Withdrew: Other: adverse event500
Withdrew: Disease progression38100
Withdrew: Physician decision530
Withdrew: Lost to follow-up110
Withdrew: Death210
Withdrew: Withdrawal by subject330
Withdrew: Other: increased qtc interval and clinical progression found010
Withdrew: Other: progressive disease (no confirming documents)010
Withdrew: Other: disease progression100
Withdrew: Other: due to anemia the investigator decided not to continue100
Withdrew: Other: due to disease progression and could not tolerate the dose100
Withdrew: Enrolled and did not receive study drug (not included in safety analysis set)200

Outcome measures

PrimaryHaematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and Platelets Parameters

The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Comparison between the cohorts was not the objective for the study. The hematology data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment

Time frame:
Baseline to EOT (approximately 6 months)
Reported as:
Count of participants · Participants
Haematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and Platelets Parameters
ParticipantsOvarianBreast CancerBoth Ovarian and Breast CancerCancer Type: Overall
Basophils Absolute Count — EOT Above Normal0000
Basophils Absolute Count — EOT Normal7212185
Basophils Absolute Count — EOT Below Normal4110051
Basophils Absolute Count — EOT Missing4816064
Eosinophils Absolute Count — EOT Above Normal2002
Eosinophils Absolute Count — EOT Normal90201111
Eosinophils Absolute Count — EOT Below Normal213024
Eosinophils Absolute Count — EOT Missing4815063
Leucocytes WBC — EOT Above Normal2103
Leucocytes WBC — EOT Normal101171119
Leucocytes WBC — EOT Below Normal278035
Leucocytes WBC — EOT Missing3112043
Lymphocytes Absolute Count — EOT Above Normal0000
Lymphocytes Absolute Count — EOT Normal7910089
Lymphocytes Absolute Count — EOT Below Normal5116168
Lymphocytes Absolute Count — EOT Missing3112043
Monocytes Absolute Count — EOT Above Normal3104
Monocytes Absolute Count — EOT Normal8414199
Monocytes Absolute Count — EOT Below Normal268034
Monocytes Absolute Count — EOT Missing4815063
Neutrophils Absolute Count — EOT Above Normal2103
Neutrophils Absolute Count — EOT Normal107191127
Neutrophils Absolute Count — EOT Below Normal216027
Neutrophils Absolute Count — EOT Missing3112043
Platelets — EOT Above Normal186125
Platelets — EOT Normal6913082
Platelets — EOT Below Normal437050
Platelets — EOT Missing3112043
PrimaryHaematology: Haemoglobin Parameters

The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. The haemoglobin parameter data were analyzed as above normal/normal/below normal and are presented as end of treatment status for the overall population . EOT = end of treatment

Time frame:
Baseline to EOT (approximately 6 months)
Reported as:
Count of participants · Participants
Haematology: Haemoglobin Parameters
ParticipantsOvarian CancerBreast CancerBoth Ovarian and Breast CancerCancer Type: Overall
EOT Above Normal0000
EOT Normal155020
EOT Below Normal115211137
EOT Missing3112043
PrimaryNumber of Participants Who Experienced a Shift in Hematology Parameters to Results Classified as Below Normal at EOT

The number of participants who experienced hematology results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment

Time frame:
Baseline to EOT (approximately 6 months)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Shift in Hematology Parameters to Results Classified as Below Normal at EOT
ParticipantsOvarian CancerBreast CancerBoth Ovarian and Breast CancerCancer Type: Overall
Basophils Absolute Count135018
Eosinophils Absolute Count82010
Leucocytes WBC176023
Lymphocytes Absolute Count208129
Monocytes Absolute Count216027
Neutrophils Absolute Count95014
Platelets234027
PrimaryNumber of Participants Who Experienced a Shift in Hemoglobin Parameters to Results Classified as Below Normal at EOT

The number of participants who experienced hemoglobin results classified as normal at Baseline which shifted to below normal at the End of Treatment visit are presented.. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. EOT = end of treatment

Time frame:
Baseline to EOT (approximately 6 months)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Shift in Hemoglobin Parameters to Results Classified as Below Normal at EOT
ParticipantsOvarian CancerBreast CancerBoth Ovarian and Breast CancerCancer Type: Overall
Number of Participants Who Experienced a Shift in Hemoglobin Parameters to Results Classified as Below Normal at EOT1711028
PrimaryNumber of Participants With Remarkable Changes in Clinical Chemistry Values Over Time as Assessed by Investigator

The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment

Time frame:
Baseline to EOT (approximately 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Remarkable Changes in Clinical Chemistry Values Over Time as Assessed by Investigator
ParticipantsOvarian CancerBreast CancerBoth Ovarian and Breast Cancer
Number of Participants With Remarkable Changes in Clinical Chemistry Values Over Time as Assessed by Investigator000
PrimaryNumber of Participants With Remarkable Changes in Physical Examination Over Time as Assessed by Investigator

Abnormal clinically significant results at Baseline and EOT are presented. The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.

Time frame:
Baseline to EOT (approximately 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Remarkable Changes in Physical Examination Over Time as Assessed by Investigator
ParticipantsOvarian CancerBreast CancerBoth Ovarian Cancer and Breast Cancer
Abnormal Clinically Significant result at Baseline — Physical Examination Status000
Abnormal Clinically Significant result at Baseline — General Appearance000
Abnormal Clinically Significant result at Baseline — Respiratory000
Abnormal Clinically Significant result at Baseline — Cardiovascular000
Abnormal Clinically Significant result at Baseline — Abdomen000
Abnormal Clinically Significant result at Baseline — Lymph Nodes000
Abnormal Clinically Significant result at Baseline — Musculoskeletal system010
Abnormal Clinically Significant result at Baseline — No response161371
Abnormal Clinically Significant result at End of Treatment — Physical Examination Status210
Abnormal Clinically Significant result at End of Treatment — General Appearance000
Abnormal Clinically Significant result at End of Treatment — Respiratory110
Abnormal Clinically Significant result at End of Treatment — Cardiovascular000
Abnormal Clinically Significant result at End of Treatment — Abdomen100
Abnormal Clinically Significant result at End of Treatment — Lymph Nodes010
Abnormal Clinically Significant result at End of Treatment — Musculoskeletal system000
Abnormal Clinically Significant result at End of Treatment — No response157351
PrimaryNumber of Participants With Remarkable Changes in Vital Signs Over Time as Assessed by Investigator

The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib. Remarkable changes were assessed by the investigator. EOT = end of treatment

Time frame:
Baseline to EOT (approximately 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Remarkable Changes in Vital Signs Over Time as Assessed by Investigator
ParticipantsOvarian CancerBreast CancerBoth Ovarian Cancer and Breast Cancer
Number of Participants With Remarkable Changes in Vital Signs Over Time as Assessed by Investigator000
PrimaryWHO Performance Status

The objective of this Phase 4 study was to assess the overall safety of Olaparib in participants with ovarian or breast cancer who were prescribed the drug in routine clinical practice based on locally approved prescribing information. The number of participants with ovarian or breast cancer planned to receive Olaparib was not predetermined and was dependent on patients in routine clinical practice eligible to receive Olaparib.

Time frame:
Baseline and End of study visit (200 days)
Reported as:
Count of participants · Participants
WHO Performance Status
ParticipantsOvarian CancerBreast CancerBoth Ovarian and Breast CancerCancer Type: Overall
Baseline — Normal activity155381194
Baseline — Restricted activity6006
Baseline — In bed less than or equal to 50% of the time0000
End of Study — Normal activity92120104
End of Study — Restricted activity7108
End of Study — In bed less than or equal to 50% of the time1001

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ovarian Cancer3/161 (1.9%)24/161 (14.9%)148/161 (91.9%)
Breast Cancer3/38 (7.9%)7/38 (18.4%)30/38 (78.9%)
Both Ovarian Cancer and Breast Cancer0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventOvarian CancerBreast CancerBoth Ovarian Cancer and Breast Cancer
Retinal vascular occlusionEye disorders0/1610/381/1
AnaemiaBlood and lymphatic system disorders12/1612/380/1
ThrombocytopeniaBlood and lymphatic system disorders0/1612/380/1
CoagulopathyBlood and lymphatic system disorders0/1611/380/1
Increased tendency to bruiseBlood and lymphatic system disorders0/1611/380/1
NeutropeniaBlood and lymphatic system disorders0/1611/380/1
Abdominal painGastrointestinal disorders3/1611/380/1
Abdominal distensionGastrointestinal disorders0/1611/380/1
ConstipationGastrointestinal disorders0/1611/380/1
AstheniaGeneral disorders1/1611/380/1
Most frequent other events
Showing 10 of 18
Most frequent other events
EventOvarian CancerBreast CancerBoth Ovarian Cancer and Breast Cancer
AstheniaGeneral disorders13/1613/381/1
AnaemiaBlood and lymphatic system disorders82/16114/380/1
ThrombocytopeniaBlood and lymphatic system disorders35/1615/380/1
NauseaGastrointestinal disorders33/1613/380/1
VomitingGastrointestinal disorders27/1614/380/1
FatigueGeneral disorders25/1613/380/1
Decreased appetiteMetabolism and nutrition disorders18/1615/380/1
LeukopeniaBlood and lymphatic system disorders18/1613/380/1
DiarrhoeaGastrointestinal disorders18/1612/380/1
ConstipationGastrointestinal disorders10/1614/380/1

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
Mean53.2 ± 8.7844.3 ± 11.8557.0 ± NA51.5 ± 10.01
Sex: Female, Male
Sex: Female, Male(Participants)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
Female163381202
Male0000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
Count of participants———0
Body mass index
Body mass index(kg/m2)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
Mean26.204 ± 4.536624.699 ± 4.728221.210 ± NA25.896 ± 4.6000
Child Bearing Potential
Child Bearing Potential(Participants)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
Yes112013
No162261189
Stage/FIGO Stage of Cancer at Screening
Stage/FIGO Stage of Cancer at Screening(Participants)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
Stage IA4206
Stage IB0101
Stage IC5005
Stage IIA1304
Stage IIB2103
Stage IIIA123015
Stage IIIB6309
Stage IIIC609069
Stage IVA4210153
Stage IVB296035
Missing2002
Previous Cancer Therapy
Previous Cancer Therapy(Participants)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
1 cancer therapy regimen28010
2 cancer therapy regimens5510166
More than 2 cancer therapy regimens106190125
No0101
WHO Performance Status
WHO Performance Status(Participants)Ovarian CancerBreast CancerBoth Ovarian Cancer and Breast CancerTotal
Normal activity157381196
Restricted activity6006
In bed less than or equal to 50% of the time0000
In bed more than 50% of the time0000
100% bedridden0000
08

Study locations

16 sites
  • Research Site
    Ahmedabad, 380009, India
  • Research Site
    Bhubaneswar, 751007, India
  • Research Site
    Chandigarh, 160012, India
  • Research Site
    Delhi, 110029, India
  • Research Site
    Faridabad, 121001, India
  • Research Site
    Guwahati, 781023, India
  • Research Site
    Kochi, 682041, India
  • Research Site
    Kolkata, 700099, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Madurai, 625107, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Mumbai, 400053, India
  • Research Site
    New Delhi, 110 085, India
  • Research Site
    New Delhi, 110005, India
  • Research Site
    New Delhi, 110063, India
  • Research Site
    Vellore, 632004, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Sep 2022, 28 months.

Results were first posted in Mar 2025, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2020
First posted
Apr 1, 2020
StartActual
May 25, 2020
Primary completionActual
Sep 30, 2022
CompletionActual
Sep 30, 2022
Results first posted
Mar 10, 2025
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04330040
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 1, 2020
Start date
May 25, 2020
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Results posted
Mar 10, 2025
Last update
Mar 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion